Johnatan Braz

[MDPI Life Sciences @LifesciMdpi]

🦠💪 Can gut microbes help combat cancer-related muscle loss?

Roy et al. review how boosting SCFA-producing gut bacteria and reducing endotoxins may help limit inflammation and muscle wasting in cancer cachexia.

🔗 https://t.co/6wgsmvqs3H

#Microbiome #CancerResearch

[Chris Beardsley @SandCResearch]

Consuming carbohydrates before an intense bout of endurance running reduces the post-exercise muscle damage and inflammation responses, likely thereby reducing fatigue and allowing faster recovery after exercise.

[Nutrients MDPI @Nutrients_MDPI]

🛡️ Selenium and Immune Defense

Rebecka A. Sadler et al. review how selenium may support antioxidant activity, innate and adaptive immunity, and gut microbiota.

🔗 https://t.co/3CWZghppCP

[Mariia Dolores @mariinavarro_h]

Olive Oil as a Modulator of Gut Microbiota and Intestinal Health: A Narrative Review from Microbial Metabolism to Host Responses https://t.co/vAFLFVJjf9 #mdpinutrients a través de @Nutrients_MDPI

[Nicholas Fabiano, MD @NTFabiano]

Lifting heavy things is one of the best things you can do for your mental health.

[MDPI Life Sciences @LifesciMdpi]

🌿 Why are flavonoids so important for plants?

Mao et al. review how plants produce and regulate flavonoids, highlighting their roles in pigmentation, stress responses, and plant development.

🔗 https://t.co/KFBA3IqBbc

#PlantScience #Flavonoids

[Antelm Pujol, MD PhD @AntelmPujol]

🚨 La verdad sobre ganar músculo que casi nadie te cuenta

🏋️‍♂️ La mayor parte de las ganancias ocurren durante los primeros 2–3 años de entrenamiento.

📉 Después, seguirás ganando músculo, pero cada vez más despacio.

🧬 La genética marca grandes diferencias: algunas personas ganarán ≈5 kg de músculo a lo largo de su vida, mientras que otras pueden superar los 20 kg.

[Nutrients MDPI @Nutrients_MDPI]

🍽️ Food allergy, food intolerance or IBS?

Andrea Pasta et al. examine overlapping symptoms and review low FODMAP, gluten free and Mediterranean dietary approaches.

Read the open access review: https://t.co/pYcAdSmFgl

#FoodAllergy #IBS

[The Lancet Diabetes & Endocrinology @TheLancetEndo]

In the August Issue:
1-year outcomes of #semaglutide, #tirzepatide, and #sleeve #gastrectomy in #obesity in type 2 #diabetes: a retrospective cohort study https://t.co/JPVrEAMgo8
#T2D

[Johnatan Braz @BrazJohnatan]

@LeticiaColin @tvglobo @gshow @novelagloboplay Chega na força do ódio, mulher. Quero ver sangue, suor e lágrimas.

[William B. Grant, PhD @wbgrant2]

Vitamin D in Obesity: Mechanisms and Clinical Impact https://t.co/UYd0ZBraxg #mdpiobesities via @ObesitiesMDPI

[Sergio Zúñiga @medicosergio]

¿Qué pasa cuándo se retira el GLP-1?

Enfoque gradual para mitigar la recuperación de peso tras la interrupción del tratamiento con GLP-1. Este marco conceptual ilustra una estrategia jerárquica para el mantenimiento del peso tras la interrupción del tratamiento con GLP-1, que progresa desde intervenciones conductuales y de estilo de vida hasta enfoques farmacológicos. Sin duda, la sostenibilidad a largo plazo depende del acceso, la asequibilidad y la capacidad del sistema sanitario.
https://t.co/3llDLTgEug

[Kevin Whelan @ProfWhelan]

What research needs to be done on nutrition and diet in #InflammatoryBowelDisease #CrohnsDisease #UlcerativeColitis?

Nutrition & IBD Group includes global experts (plus me 😉) in research and clinical practice in diet & IBD

Free access for 50 days!👉 https://t.co/fBj5Gt9Ms6

[🔬 RicardoMontes @_MCRicardo_]

Dietary approaches to support cognition in older adults: a systematic review

▶️ This systematic review evaluates the efficacy of the Mediterranean, Nordic, Okinawan, & plant-based dietary approaches in mitigating cognitive decline & reducing dementia risk in older populations.

https://t.co/K7c7Y8ju8V @_INPST @HealthyFellow
@JuhanaHarju @tatiann69922625
High adherence to whole-food, holistic dietary patterns, specifically the Mediterranean, Nordic, Okinawan, & plant-based approaches, consistently mitigates cognitive decline & reduces the risk of Alzheimer's disease & related dementias in older adults.

[Cristina Tejera @cristinatejerap]

Nuevo consenso @EASOobesity @efad_org @ECPObesity en @TheLancetEndo sobre incretinas (GLP-1 y agonistas duales GLP-1/GIP) en obesidad.
Estas terapias transforman el manejo de la obesidad, pero el acompañamiento importa tanto ( o más) que el fármaco.

💪 Músculo. La masa magra supone ~24-30% del peso perdido. En fase de pérdida: 1,0-1,5 g/kg de peso ajustado/día de proteína de calidad , repartida entre comidas + entrenamiento de fuerza. ( personalmente voy a por el 1,5)

🥦 Lo básico bien hecho. Fibra ≥25 g/día, 2-2,5 L de líquidos ( agua) , comida real. Para los efectos digestivos: titulación lenta y comidas bajas en grasa.

🧠 Psicología. Cambia el ruido con la comida, el placer y a veces la propia identidad. Conviene revisar la conducta alimentaria y vigilar la sustitución de recompensa y el malestar tras perder peso.

Y sin olvidar hueso, adultos mayores y obesidad sarcopénica.

Merece lectura sosegada 👇 🔗

https://t.co/rFTBDTFkYv

[Cristina Tejera @cristinatejerap]

¿Qué pasa cuando se deja un GLP-1? Hasta el 65% lo abandona en el primer año, y al hacerlo se recupera alrededor de dos tercios del peso perdido en 12 meses. También se revierten las mejoras en glucemia, presión arterial y lípidos y podrían atenuarse los beneficios CV. Al retirar el fármaco cae la leptina, el PYY y la CCK, sube la grelina y aparece termogénesis adaptativa con menor gasto energético. El cuerpo defiende su peso. ❗️
➡️La obesidad es una enfermedad crónica, y su tratamiento también tiene que serlo. El GLP-1 no es una intervención con fecha de caducidad, sino una pieza más dentro de un acompañamiento en el estilo de vida a largo plazo.

📄 https://t.co/6IpNqCNt1m

[CME INDIA @CMEINDIA1]

CME INDIA Clinical Pearls

GLP-1 Therapy Stopped? Weight Comes Back Fast

Source: eClinicalMedicine / The Lancet, 2026

💉 1. GLP-1 drugs are powerful — but not “short-course antibiotics” for obesity.
Semaglutide/tirzepatide can produce 10–30% weight loss, but stopping therapy commonly leads to rapid regain.

⚠️ 2. STEP-1 warning:
After stopping semaglutide, patients regained nearly two-thirds of lost weight within 1 year.

⚠️ 3. SURMOUNT-4 warning:
After tirzepatide withdrawal, weight regain was substantial, while those continuing therapy maintained or lost more weight.

🫀 4. Weight regain is not cosmetic only.
Stopping GLP-1 therapy can reverse benefits in HbA1c, BP, lipids, waist circumference, and cardiometabolic risk.

🧠 5. Biology fights back.
After discontinuation:
⬆️ hunger hormones
⬇️ satiety hormones
⬇️ resting energy expenditure
➡️ strong drive for regain.

🍽️ 6. Lifestyle alone is often insufficient unless structured.
High-protein diet, calorie control, fibre-rich foods, Mediterranean/DASH pattern, and regular monitoring are useful — but need sustained follow-up.

🏋️ 7. Exercise prescription matters.
Weight maintenance often needs 200–300 min/week moderate-vigorous activity plus resistance training to preserve muscle and metabolic capacity.

🧘 8. Behavioural therapy is not optional.
CBT, self-weighing, food logs, digital coaching, relapse-prevention plans and peer support may reduce rebound.

💊 9. No proven “best tapering protocol” yet.
Dose tapering, low-dose maintenance, or switching to other anti-obesity drugs are promising but still not supported by strong RCT evidence.

✅ 10. Practical CME INDIA message:
GLP-1 therapy should be framed as part of chronic obesity care, not a temporary weight-loss injection.
Stopping needs a maintenance plan before the last dose.

https://t.co/0mxkoTdANV

[Nick Krontiris @nick_krontiris]

This umbrella review finds that the evidence overall suggests that high consumption of ultra-processed foods is likely to be concomitant with a wide range of adverse health outcomes in both children and adults.

[Nick Krontiris @nick_krontiris]

This review aims to synthesize available evidence across lifestyle, behavioral, pharmacological, and procedural domains to identify potential strategies that may help mitigate weight regain following GLP-1 treatment discontinuation.

[Antonio García-Hermoso @a_garciahermoso]

Los fármacos tipo GLP-1 pueden ayudar a perder peso, pero ¿qué pasa cuando se dejan? 🤔⚖️

La clave no es solo “bajar kilos”, sino mantener hábitos, apoyo y ejercicio a largo plazo 🥗🏃‍♀️💬

https://t.co/DEzM3JXJxw